BioStem Technologies, Inc.
BSEM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001658678
No open-market purchases or sales by BioStem Technologies, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by BioStem Technologies, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for BioStem Technologies, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Poe Brandon | Chief Financial Officer | 58,062 | Sep 17, 2026 | 2 |
| Smith-Van Vurst Andrew | Chief Operating Officer | 1,539,809 | Sep 17, 2026 | 1 |
| Matuszewski Jason | Chief Executive Officer | 1,303,552 | Sep 17, 2026 | 1 |
| Warrington Kenneth Howard Jr | Director | 33,928 | Sep 17, 2026 | 2 |
| Fortunato Michael A | Chief Accounting Officer | 68,664 | Sep 17, 2026 | 2 |
| Hassett Barry | Chief Commercial Officer | 5,003 | Sep 11, 2026 | 1 |
| Ungrodt Jodi | Director | 11,295 | Aug 28, 2026 | 1 |
| Glickman Mark A | Director | 7,671 | Aug 28, 2026 | 1 |
| Lesser Hannaway Rayna | Director | 7,671 | Aug 28, 2026 | 1 |
| Sonenreich Steven D | Director | 7,671 | Aug 28, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.